APOGEE BIOTECHNOLOGY CORPORATION

Basic Information

1214 Research Blvd
Suite 2014
HUMMELSTOWN, PA, 17036-9196

Company Profile

n/a

Additional Details

Field Value
DUNS: 95628348
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Protection Against Chemotherapy-Induced Gastrointestinal Mucositis by a Sphingosi

    Amount: $224,116.00

    DESCRIPTION (provided by applicant): Mucositis caused by excessive inflammation within the gastrointestinal tract is a costly and debilitating toxicity commonly experienced by patients receiving radia ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi

    Amount: $593,448.00

    DESCRIPTION (provided by applicant): Radiation-induced production of pro-inflammatory and pro-fibrotic cytokines results in chronic and irreversible damage to the lungs. To date, no agent has demonst ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Treatment of Inflammatory Bowel Disease with Ceramidase Inhibitors

    Amount: $316,916.00

    DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human neutral ceramidase (ASAH2) that are effective as therapeutic agents for Inflammatory Bowel Disease ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of cancers arising preferentially within immune compromised hosts, including patients inf ...

    STTR Phase I 2010 Department of Health and Human Services
  5. Optimization of dipeptide-linked benzimidazole topoisomerase 1 poisons

    Amount: $260,988.00

    DESCRIPTION (provided by applicant): Derivatives of camptothecin (CPT) that inhibit Topoisomerase I (Top1) activity have demonstrated clinical utility in the treatment of various cancers. However, lim ...

    STTR Phase I 2009 Department of Health and Human Services
  6. Improvement of Liver Transplantation by a Sphingosine Kinase Inhibitor

    Amount: $526,907.00

    DESCRIPTION (provided by applicant): Severe shortages of donor organs limit the use of orthotopic liver transplantation (LT), the only proven therapy for end-stage liver diseases. Primary non-function ...

    STTR Phase I 2009 Department of Health and Human Services
  7. Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

    Amount: $996,642.00

    DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid art ...

    SBIR Phase II 2008 Department of Health and Human Services
  8. Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents

    Amount: $953,134.00

    DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents for retinal and choroidal vascula ...

    SBIR Phase II 2007 Department of Health and Human Services
  9. Sphingosine Kinase Inhibitors as Anti-IBD Agents

    Amount: $1,694,410.00

    DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in ...

    SBIR Phase II 2006 Department of Health and Human Services
  10. Anti-Atherosclerosis Agents Targeting Sphingosine Kinase

    Amount: $219,476.00

    DESCRIPTION (provided by applicant): Principal Investigator/Program Director: French, Kevin J. Abstract: The long-term goal of this program is to develop inhibitors of human sphingosine kinase (SK) th ...

    SBIR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government